UnitedHealth Group is executing a successful turnaround, reaffirming a Buy rating as shares remain undervalued versus fair value estimates. UNH raised 2026 adjusted diluted EPS guidance to $19.50–$20.00, reflecting strong margin discipline, AI-driven efficiencies, and robust Optum growth. Balance sheet strength is evident with an A+ S&P rating, improving debt metrics, and a secure, sector-beating 2.4% forward dividend yield.
Three companies with nothing in common all sent dividend checks on the same September day, but only one of them handed shareholders a freshly raised rate.
I still view UnitedHealth as a fully playable recovery, with MCR improving from 89.4% to 86.7% and 2026 EPS guidance already raised twice. Management is deliberately giving up lower-quality membership to rebuild margins, while operating cash flow guidance has increased from >$18B to ~$24B. The broader health care setup also looks attractive, with the sector heavily lagging the S&P 500 and a more defensive macro backdrop developing.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
UnitedHealth (UNH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The next quarterly UnitedHealth (NYSE: UNH) dividend is coming next week, on Tuesday, September 22, 2026, when all shareholders of record as of the close of business on September 14, 2026, will receive $2.32 per share.
UnitedHealth Group (UNH) remains a buy, with attractive valuation and solid fundamentals despite recent underperformance versus the S&P 500. Q2 results delivered an earnings triple play: beats on revenue and EPS, plus raised FY 2026 guidance; medical loss ratio held at 86.7%. Consensus EPS upgrades (24 upgrades, zero downgrades) and a 6.9% FCF yield support confidence in UNH's long-term growth trajectory.
In the latest trading session, UnitedHealth Group (UNH) closed at $379.09, marking a -2.37% move from the previous day.
UNH's TPG deal brings local support and investment to Florida WellMed clinics as Optum targets faster growth and stronger profitability.
UnitedHealth Group Incorporated (UNH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
UnitedHealth Group NYSE: UNH executives said the company's turnaround remained on track, citing continued strength in Medicare Advantage, Medicaid performance that is tracking toward the favorable end of expectations, and operational improvements at Optum Health.